Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).

Date publication

avril 2022

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr AVEROUS Gerlinde , Dr LEROUX Agnès

Tous les auteurs :
Henno S, Jeanne C, Rouge TM, Genestie C, Treilleux I, Croce S, Just PA, Le Frere-Belda MA, Guinaudeau E, Penault-Llorca F, Arnould L, Mery-Lamarche E, Leroux A, Lemaire AS, Averous G, Renaud O, Charafe-Jauffret E, Bonneau C, Leaha C, Ray-Coquard I, Devouassoux-Shisheboran M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35393217

Résumé

Since 2010, the network of rare malignant tumors of the ovary (TMRG) was developed to optimize the management of patients, also allowing a histological second opinion of rare ovarian tumors. The aim of this work was to study the contribution of second opinion to improve histological diagnostic accuracy on ovarian rare malignant tumors included in the TMRG database.

Mots clés

Concordance evaluation, Network, Ovarian tumor, Pathological discordance, Pathological review, Rare ovarian tumor

Référence

Gynecol Oncol. 2022 Apr 4;: